Scheduled or emergent cardiac stent placement
A prospective, open-label, multi-center, observational, single-arm registry designed to evaluate the XIENCE™ V Everolimus Eluting Coronary Stent System (XIENCE™ VEECSS)
To evaluate the continued safety and effectiveness of the XIENCE V EECSS recently approved for use by the Food and Drug Administration during commercial use in real world settings.
Key Inclusion Criteria
Agreement to participate in this study by signing the Institutional Review Board approved informed consent form.
Key Exclusion Criteria
The inability to obtain an informed consent. Age limit to be determined by physician.